2019 Form 10-K Financial Statement
#000156459020009016 Filed on March 05, 2020
Income Statement
| Concept | 2019 | 2018 Q4 | 2018 Q3 |
|---|---|---|---|
| Revenue | $1.517M | $380.0K | $379.0K |
| YoY Change | -0.2% | -68.15% | 24.26% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $16.06M | $3.890M | $4.130M |
| YoY Change | -7.11% | -4.66% | 16.01% |
| % of Gross Profit | |||
| Research & Development | $42.99M | $15.82M | $14.10M |
| YoY Change | -28.48% | -4.69% | 15.65% |
| % of Gross Profit | |||
| Depreciation & Amortization | $90.00K | $80.00K | |
| YoY Change | 15.38% | -46.67% | |
| % of Gross Profit | |||
| Operating Expenses | $59.06M | $19.71M | $18.22M |
| YoY Change | -23.69% | -4.69% | 15.68% |
| Operating Profit | -$57.54M | -$19.33M | -$17.84M |
| YoY Change | -24.17% | -0.8% | 15.51% |
| Interest Expense | $1.570M | $520.0K | $488.0K |
| YoY Change | -19.07% | 13.04% | 18.73% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $1.492M | $496.0K | $503.0K |
| YoY Change | -22.09% | 28.83% | 40.5% |
| Pretax Income | -$56.05M | -$18.84M | -$17.34M |
| YoY Change | -24.22% | -1.36% | 14.91% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$56.05M | -$18.84M | -$17.34M |
| YoY Change | -24.22% | -1.4% | 14.91% |
| Net Earnings / Revenue | -3694.59% | -4957.11% | -4574.67% |
| Basic Earnings Per Share | -$1.84 | ||
| Diluted Earnings Per Share | -$1.84 | -$702.5K | -$680.8K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 30.49M | 23.36M | |
| Diluted Shares Outstanding | 30.49M |
Balance Sheet
| Concept | 2019 | 2018 Q4 | 2018 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $61.10M | $81.60M | $91.50M |
| YoY Change | -25.12% | -37.85% | -24.69% |
| Cash & Equivalents | $24.60M | $33.77M | $26.71M |
| Short-Term Investments | $36.50M | $47.80M | $64.80M |
| Other Short-Term Assets | $1.200M | $1.500M | $4.100M |
| YoY Change | -20.0% | -16.67% | 115.79% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $62.30M | $83.35M | $95.85M |
| YoY Change | -25.21% | -37.54% | -22.69% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $1.000M | $373.0K | $396.0K |
| YoY Change | 150.0% | 39.7% | 38.46% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $0.00 | ||
| YoY Change | -100.0% | ||
| Other Assets | $200.0K | $219.0K | $225.0K |
| YoY Change | 0.0% | -5.19% | -4.66% |
| Total Long-Term Assets | $1.200M | $592.0K | $621.0K |
| YoY Change | 100.0% | -84.19% | 18.97% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $62.30M | $83.35M | $95.85M |
| Total Long-Term Assets | $1.200M | $592.0K | $621.0K |
| Total Assets | $63.50M | $83.94M | $96.47M |
| YoY Change | -24.31% | -38.81% | -22.51% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $6.200M | $1.439M | $3.180M |
| YoY Change | 342.86% | -35.53% | 41.59% |
| Accrued Expenses | $10.70M | $13.10M | $12.30M |
| YoY Change | -18.32% | 9.17% | 14.95% |
| Deferred Revenue | $1.517M | $1.517M | |
| YoY Change | -3.56% | ||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $18.40M | $16.11M | $17.02M |
| YoY Change | 14.29% | 1.94% | 19.77% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $13.60M | $136.0K | $148.0K |
| YoY Change | -8.11% | -56.13% | -44.57% |
| Total Long-Term Liabilities | $13.60M | $14.79M | $15.18M |
| YoY Change | -8.11% | -13.38% | 11.83% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $18.40M | $16.11M | $17.02M |
| Total Long-Term Liabilities | $13.60M | $14.79M | $15.18M |
| Total Liabilities | $31.90M | $30.89M | $32.19M |
| YoY Change | 3.24% | -6.01% | 15.89% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$439.4M | -$420.6M | |
| YoY Change | 20.02% | 21.2% | |
| Common Stock | $492.5M | $2.000K | |
| YoY Change | 4.66% | -100.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $31.60M | $53.05M | $64.27M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $63.50M | $83.94M | $96.47M |
| YoY Change | -24.31% | -38.81% | -22.51% |
Cashflow Statement
| Concept | 2019 | 2018 Q4 | 2018 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$56.05M | -$18.84M | -$17.34M |
| YoY Change | -24.22% | -1.4% | 14.91% |
| Depreciation, Depletion And Amortization | $90.00K | $80.00K | |
| YoY Change | 15.38% | -46.67% | |
| Cash From Operating Activities | -$50.61M | -$15.04M | -$18.47M |
| YoY Change | -26.15% | 18.24% | 81.43% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | -$20.00K | $0.00 |
| YoY Change | -100.0% | -50.0% | -100.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $12.78M | $15.98M | $3.510M |
| YoY Change | -75.23% | 905.03% | -49.57% |
| Cash From Investing Activities | $12.78M | $15.96M | $3.510M |
| YoY Change | -75.13% | 929.68% | -49.28% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 28.57M | 6.150M | 9.460M |
| YoY Change | 81.64% | -75.99% | 836.63% |
| NET CHANGE | |||
| Cash From Operating Activities | -50.61M | -15.04M | -18.47M |
| Cash From Investing Activities | 12.78M | 15.96M | 3.510M |
| Cash From Financing Activities | 28.57M | 6.150M | 9.460M |
| Net Change In Cash | -9.261M | 7.070M | -5.500M |
| YoY Change | 559.62% | -51.04% | 144.44% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$50.61M | -$15.04M | -$18.47M |
| Capital Expenditures | $0.00 | -$20.00K | $0.00 |
| Free Cash Flow | -$50.61M | -$15.02M | -$18.47M |
| YoY Change | -26.35% | 18.45% | 82.15% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
13133000 | |
| CY2018Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
136000 | |
| CY2018Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
27140484 | |
| CY2019 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1517000 | |
| CY2019 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
24609000 | |
| CY2018 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2018Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
101000 | |
| CY2019Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
35166000 | |
| CY2017 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
48201000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
219000 | |
| CY2018Q4 | us-gaap |
Assets
Assets
|
83938000 | |
| CY2018Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1439000 | |
| CY2018Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
13149000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1517000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1517000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
478000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
5000 | |
| CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
17287000 | |
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
15861000 | |
| CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
77393000 | |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
64062000 | |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-61954000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
13557000 | |
| CY2018Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
14650000 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
62331000 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2556000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
281000 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
716000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
10195000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
31925000 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
197000 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
63525000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16105000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6178000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
18368000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q2 | dei |
Entity Public Float
EntityPublicFloat
|
208300000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-25000 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
527067000 | |
| CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-73961000 | |
| CY2018Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
14786000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
30891000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
419000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
373000 | |
| CY2019 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2018Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
47142000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2334000 | |
| CY2019 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
33769000 | |
| CY2018Q4 | us-gaap |
Assets Current
AssetsCurrent
|
83346000 | |
| CY2019 | sndx |
Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering
|
13032000 | |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-73961000 | |
| CY2019 | sndx |
Stock Issued During Period Value Common Stock Warrant With Direct Offering
StockIssuedDuringPeriodValueCommonStockWarrantWithDirectOffering
|
3446000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6005000 | |
| CY2019 | us-gaap |
Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
|
182000 | |
| CY2019 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
178000 | |
| CY2017 | sndx |
Stock Issued During Period Value Pre Funded Common Stock Warrant
StockIssuedDuringPeriodValuePreFundedCommonStockWarrant
|
1875000 | |
| CY2017 | sndx |
Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses
|
93000 | |
| CY2019 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1492000 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-56047000 | |
| CY2019 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
25000 | |
| CY2018 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
118000 | |
| CY2019 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-56022000 | |
| CY2018 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-73843000 | |
| CY2017 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-61001000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
84139000 | |
| CY2017 | sndx |
Stock Issued During Period Value Follow On Offering Net Of Offering Cost
StockIssuedDuringPeriodValueFollowOnOfferingNetOfOfferingCost
|
48675000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
277000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
59000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5450000 | |
| CY2017 | sndx |
Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
|
1705000 | |
| CY2017 | us-gaap |
Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
|
97000 | |
| CY2017 | sndx |
Stock Issued During Period Value Direct Stock Placement Net
StockIssuedDuringPeriodValueDirectStockPlacementNet
|
24918000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
104319000 | |
| CY2018 | sndx |
Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
|
15497000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
26000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6201000 | |
| CY2018 | us-gaap |
Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
|
198000 | |
| CY2018 | us-gaap |
Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
|
16780000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
16780000 | |
| CY2019 | sndx |
Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
|
830000 | |
| CY2019 | sndx |
Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
|
10902000 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2017 | sndx |
Adjustments To Additional Paid In Capital Follow On Offering Cost
AdjustmentsToAdditionalPaidInCapitalFollowOnOfferingCost
|
3665000 | |
| CY2018 | sndx |
Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
|
67000 | |
| CY2019 | sndx |
Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
|
34000 | |
| CY2017 | sndx |
Stock Issued During Period Value Direct Offering Common Stock Warrant
StockIssuedDuringPeriodValueDirectOfferingCommonStockWarrant
|
1571000 | |
| CY2017 | sndx |
Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
|
98000 | |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-60802000 | |
| CY2018 | us-gaap |
Depreciation
Depreciation
|
78000 | |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
76000 | |
| CY2017 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-223000 | |
| CY2019 | sndx |
Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
|
359000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6201000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5450000 | |
| CY2017 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-8000 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
329000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-194000 | |
| CY2018 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1517000 | |
| CY2017 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
2892000 | |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
5305000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-68531000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-47371000 | |
| CY2017 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
152263000 | |
| CY2017 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
135275000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-17072000 | |
| CY2019 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
182000 | |
| CY2017 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
97000 | |
| CY2017 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
277000 | |
| CY2018 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
8000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
15729000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
75722000 | |
| CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1404000 | |
| CY2017 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
11279000 | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
24110000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
24724000 | |
| CY2019Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
115000 | |
| CY2018Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
216000 | |
| CY2017Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
221000 | |
| CY2019 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndax Pharmaceuticals, Inc. (“the Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, Class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-L1 antagonists. The Company’s pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as SNDX-5613, a selective inhibitor targeting the binding interaction of menin with the mixed lineage leukemia (“MLL”) protein. The Company plans to continue to leverage the technical and business expertise of its management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand its pipeline.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company’s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before any of its product candidates is approved, if ever, and the Company begins to generate revenue from sales of such product candidates. Accordingly, management expects to incur substantial losses on the ongoing development of its product candidates and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s management believes that the cash, cash equivalents and short-term investments balances as of December 31, 2019, in combination with the net proceeds of its January 2020 equity financing and February 2020 debt financing (see Note 19), should enable the Company to maintain its planned operations for at least twelve months from the date these financial statements were issued. The Company’s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and general and administrative activities. </p> | |
| CY2019 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions. </p> | |
| CY2019 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, restricted cash, and short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company’s cash, cash equivalents, and short-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company’s available-for-sale investments primarily consist of government money market funds, corporate debt securities, commercial paper, credit card asset-backed securities and overnight deposits and potentially subject the Company to concentrations of credit risk. </p> | |
| CY2019 | us-gaap |
Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
|
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees and Indemnifications </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 14) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company’s lease. Through December 31, 2019, the Company had not experienced any losses related to these indemnification obligations and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p> | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
141000 | |
| CY2019Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
9000 | |
| CY2018Q4 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
14000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
591000 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
608000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
310000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
235000 | |
| us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | ||
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
36336000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
51666000 | |
| CY2019 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2019 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
0 | |
| CY2019Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
1300000 | |
| CY2019Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
1300000 | |
| CY2019 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
| CY2019 | us-gaap |
Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
|
true | |
| CY2019Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
897000 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.14 | |
| CY2019 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
447000 | |
| CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
566000 | |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
569000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
585000 | |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
588000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
394000 | |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
395000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
59000 | |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
59000 | |
| CY2019Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1038000 | |
| CY2018Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1611000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
5000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
5000 | |
| CY2018Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
27000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
36336000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
51641000 | |
| CY2019Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
1297000 | |
| CY2018Q4 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
663000 | |
| CY2019Q4 | us-gaap |
Supplies
Supplies
|
166000 | |
| CY2018Q4 | us-gaap |
Supplies
Supplies
|
101000 | |
| CY2019Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
116000 | |
| CY2018Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
253000 | |
| CY2019Q4 | sndx |
Reimbursable Costs
ReimbursableCosts
|
416000 | |
| CY2018Q4 | sndx |
Reimbursable Costs
ReimbursableCosts
|
797000 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
6.99 | |
| CY2019 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
25857 | |
| CY2019Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
214000 | |
| CY2018Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
188000 | |
| CY2019Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
347000 | |
| CY2018Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
332000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
403000 | |
| CY2018Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
484000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2800000 | |
| CY2018Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2804000 | |
| CY2019Q4 | sndx |
Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
|
6726000 | |
| CY2018Q4 | sndx |
Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
|
9726000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
266000 | |
| CY2018Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
135000 | |
| CY2019Q1 | sndx |
Number Of Series Of Warrants
NumberOfSeriesOfWarrants
|
2 | |
| CY2019Q1 | sndx |
Gross Proceeds From Offering
GrossProceedsFromOffering
|
27600000 | |
| CY2019Q1 | sndx |
Offering Cost
OfferingCost
|
200000 | |
| CY2019Q4 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P1Y4M24D | |
| CY2019Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
16595598 | |
| CY2019 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6005000 | |
| CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6201000 | |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5450000 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y11M19D | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M24D | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y7D | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7695 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7628 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7386 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0229 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0269 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0202 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.0000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4252983 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1964025 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
134140 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6057011 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3620626 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
5655008 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.23 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
6.86 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
9.85 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.50 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.93 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
8.64 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3M18D | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y2M12D | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y1M6D | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y1M6D | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
66000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
6306000 | |
| CY2019Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
3114000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
5373000 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.81 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.17 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | |
| CY2019 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
119000 | |
| CY2018 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
126000 | |
| CY2017 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
106000 | |
| CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2018 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.68 | |
| CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
7850 | |
| CY2017 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
46680 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
9000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
16410000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
12684000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
4156000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
3443000 | |
| CY2019Q4 | sndx |
Deferred Tax Assets Capitalized Start Up And Costs Research And Development Costs Net
DeferredTaxAssetsCapitalizedStartUpAndCostsResearchAndDevelopmentCostsNet
|
55452000 | |
| CY2018Q4 | sndx |
Deferred Tax Assets Capitalized Start Up And Costs Research And Development Costs Net
DeferredTaxAssetsCapitalizedStartUpAndCostsResearchAndDevelopmentCostsNet
|
59331000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
3334000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
3690000 | |
| CY2019Q4 | sndx |
Deferred Tax Liabilities Depreciation And Amortization Of Capitalized Cost
DeferredTaxLiabilitiesDepreciationAndAmortizationOfCapitalizedCost
|
-13000 | |
| CY2018Q4 | sndx |
Deferred Tax Liabilities Depreciation And Amortization Of Capitalized Cost
DeferredTaxLiabilitiesDepreciationAndAmortizationOfCapitalizedCost
|
11550000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
828000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
|
630000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
4223000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
3423000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
84416000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
71651000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
84416000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
71651000 | |
| CY2019 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
12800000 | |
| CY2018 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
17200000 | |
| CY2019 | us-gaap |
Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
|
The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by $12.8 million and $17.2 million in 2019 and 2018, respectively, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards and capitalized research and development costs. | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
68000000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
33100000 | |
| CY2019 | sndx |
Deferred Tax Assets Operating Loss Carryforwards Expiration Period
DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod
|
2025 | |
| CY2018Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
163000 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
163000 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
241000 | |
| CY2019 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
0 | |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
|
78000 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
163000 | |
| CY2017 | us-gaap |
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
|
50000 | |
| CY2017 | sndx |
Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
|
59000 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
379000 | |
| CY2019Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
379000 | |
| CY2019Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
379000 | |
| CY2019Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
380000 | |
| CY2019Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q2 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q3 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q4 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11279000 | |
| CY2019Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12290000 | |
| CY2019Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9923000 | |
| CY2019Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9502000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3911000 | |
| CY2019Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3463000 | |
| CY2019Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3605000 | |
| CY2019Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5083000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
15190000 | |
| CY2019Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
15753000 | |
| CY2019Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
13528000 | |
| CY2019Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
14585000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14811000 | |
| CY2019Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15374000 | |
| CY2019Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13149000 | |
| CY2019Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14205000 | |
| CY2019Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
509000 | |
| CY2019Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
458000 | |
| CY2019Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
320000 | |
| CY2019Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
205000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14302000 | |
| CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14916000 | |
| CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12829000 | |
| CY2019Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14000000 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.53 | |
| CY2019Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.47 | |
| CY2019Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.41 | |
| CY2019Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.44 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27023466 | |
| CY2019Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31605279 | |
| CY2019Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31630639 | |
| CY2019Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
31640484 | |
| CY2018Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
379000 | |
| CY2018Q2 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
379000 | |
| CY2018Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
379000 | |
| CY2018Q4 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
380000 | |
| CY2018Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2018Q2 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2018Q3 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2018Q4 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
us-gaap:LicenseMember | |
| CY2018Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15339000 | |
| CY2018Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14851000 | |
| CY2018Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14095000 | |
| CY2018Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15821000 | |
| CY2018Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4791000 | |
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4479000 | |
| CY2018Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4125000 | |
| CY2018Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3892000 | |
| CY2018Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
20130000 | |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
19330000 | |
| CY2018Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
18220000 | |
| CY2018Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
19713000 | |
| CY2018Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19751000 | |
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-18951000 | |
| CY2018Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17841000 | |
| CY2018Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19333000 | |
| CY2018Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
353000 | |
| CY2018Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
563000 | |
| CY2018Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
503000 | |
| CY2018Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
496000 | |
| CY2018Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19398000 | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18388000 | |
| CY2018Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17338000 | |
| CY2018Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18837000 | |
| CY2018Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.79 | |
| CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.74 | |
| CY2018Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.68 | |
| CY2018Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.70 | |
| CY2018Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24478269 | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24705441 | |
| CY2018Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25471587 | |
| CY2018Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26804089 |
